Related Experiment Video

Updated: Aug 10, 2026

Assaying Protein Kinase Activity with Radiolabeled ATP
08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

An enzyme-linked immunosorbent assay for the Raf/MEK1/MAPK signaling cascade

R Mallon1, L R Feldberg, S C Kim

  • 1Oncology Research, Wyeth-Ayerst Research, 401 North Middletown Road, Pearl River, New York, 10965, USA. mallonr@war.wyeth.com

Analytical Biochemistry
|June 20, 2001
PubMed

Insights

A new ELISA assay effectively monitors Raf and MEK1 kinase activity, crucial for cancer research. This tool screens compounds for potential cancer therapeutics targeting the Ras-MAPK pathway.

Area of Science:

  • Cellular signaling
  • Molecular biology
  • Cancer research

Background:

  • The Ras-MAPK pathway transmits signals for cell growth and proliferation.
  • Aberrant Ras activation is implicated in roughly 30% of human cancers.
  • Kinase components of this pathway are key targets for cancer drug development.

Purpose of the Study:

  • To develop a high-throughput assay for monitoring Raf and MEK1 kinase activity.
  • To enable screening of compounds for inhibitors of the Ras-MAPK pathway.

Main Methods:

  • Development of a nonradioactive enzyme-linked immunosorbent assay (ELISA).
  • Utilized antibodies specific for phosphorylated MAPK to detect kinase activity.
  • Assay measures Raf-MEK1 and MEK1-MAPK phosphorylation events.

Main Results:

  • The developed ELISA method successfully monitors Raf and MEK1 kinase activity.
  • The assay can identify inhibitors targeting Raf and/or MEK1.
  • Screened large libraries of random compounds for potential drug candidates.

Conclusions:

  • The high-throughput ELISA is a valuable tool for cancer drug discovery.
  • The assay facilitates the identification of inhibitors within the Raf/MEK1/MAPK cascade.
  • This method aids in targeting the Ras-MAPK pathway for cancer therapy.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence09:58

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence

Published on: May 2, 2025

Related Concept Videos

Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or quantified.